Chemoradiation plus immunotherapy and surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether adding an immune medicine (durvalumab) to standard chemoradiation, followed by surgery, improves outcomes for people with certain operable non-small cell lung cancers. It also checks safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer confirmed by biopsy.
- Your scans show no spread to distant organs, and lymph node involvement fits specific CT/PET scan patterns.
- Surgeons think you can have curative surgery (lobectomy, sometimes bilobectomy) without major invasion into critical structures like the spine, major blood vessels, or certain airway/esophagus areas.
- You can safely undergo chemoradiation: the radiation can be given per the protocol and the radiation field will not reach the lung hilum (the central lung area).
- Your lung and heart function meet safety thresholds, and your breathing oxygen level on room air is above 93%.
- You are age 20 to 75, have good daily function (ECOG 0–1), and can take medicines by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
This trial tests a combination of immunotherapy (durvalumab) and chemotherapy before surgery or radiation for people with stage III lung cancer that is on the edge of being removable. The goal is to shrink the tumor enough to allow surgery or more effective radiation.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.